Can Radix Regenerative turn BHRT, peptides and regenerative medicine into a scalable clinical partner model?
Radix Regenerative launches BHRT, peptide and regenerative medicine platform for U.S. clinics. Find out what this changes for providers.
Pharma & Biotech
Pharma & Biotech
OLLY launches Precise Probiotics: Is targeted gut health the next big wellness trend
Explore how OLLY’s Precise Probiotics could reshape gut health trends and personalized wellness. Find out what this means for consumers today.
Pharma & Biotech
Vyome’s VT-1953 Phase 2 data signals breakthrough in malignant fungating wound care
Vyome’s VT-1953 shows strong Phase 2 results in cancer wound care. Find out how this breakthrough could reshape supportive oncology treatment today.
Pharma & Biotech
Can Vistagen turn refisolone into a fast-acting alternative for menopausal hot flashes?
Vistagen advances refisolone for menopausal hot flashes after FDA clearance. Find out what this means for non-hormonal treatment options.
Pharma & Biotech
How OrganaBio’s RxMP partnership could advance RMP-402 for severe bleeding control
Find out how OrganaBio’s RxMP partnership could advance RMP-402, a first-in-class therapy for severe bleeding control.
Pharma & Biotech
Why DemeRx’s FDA-cleared DMX-1001 IND could matter for alcohol use disorder drug development
Find out how DemeRx’s DMX-1001 IND acceptance could reshape alcohol use disorder drug development and what risks remain.
Pharma & Biotech
Can logic-gated CAR T therapies finally crack solid tumors? A2 Biotherapeutics shares early ASCO data
A2 Biotherapeutics shares EVEREST-2 CAR T data at ASCO 2026. Find out what this means for solid tumor therapy and next-gen cell treatments.
Pharma & Biotech
Is lysergide finally going mainstream? Definium Therapeutics bets on DT120 ODT clinical momentum
Can DT120 ODT transform mental health treatment? Explore Definium Therapeutics’ pivotal trials and what they mean for psychedelic psychiatry.
Pharma & Biotech
Is this the migraine breakthrough Big Pharma missed? Kallyope’s elismetrep hints at a whole new treatment playbook
Kallyope’s elismetrep migraine data point to a new TRPM8 treatment pathway. Find out what Phase 3 could prove next.
Pharma & Biotech
What Epitopea’s MHRA-approved OVACT trial signals for off-the-shelf cancer vaccines
Find out how Epitopea’s CryptiVax-1001 trial could reshape RNA cancer vaccines and ovarian cancer treatment strategies.